120
Participants
Start Date
August 13, 2025
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
Daily low-dose PDE5 inhibitor therapy
Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.
Testosterone therapy as per clinical guidelines.
Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.
RECRUITING
"UCI Urology , Men's Health Center"
University of California, Irvine
OTHER